Amarin Corporation plc, each representing one Ordinary Share (AMRN) Company Bio
Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company was founded in 1989 and is based in Dublin, Ireland.
AMRN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Amarin Corp Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Amarin Corp Plc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Amarin Corp Plc ended up being:
The company's debt burden, as measured by earnings divided by interest payments, is -2.56 -- which is good for besting merely 14.5% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than only 6.2% of the free cash flow producing stocks we're observing.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
AGHC, ALC, ATRS, MOR, and PACB can be thought of as valuation peers to AMRN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
The markets might be in turmoil, but spare a thought for the current woes at biotech Amarin (AMRN). Over the past 7 trading sessions, shares have retreated by 44% as investors charged to the exit doors following a botched date in court.Last week, an appeals court rejected Amarin’s appeal concerning a
Background If unaware, the title is a quote from Yogi Berra, that great baseball player and common-man philosopher. So, when the U.S. Court of Appeals affirmed the decision of the U.S. District Court for the district of Nevada and ruled Amarin’s (AMRN) patents for Vascepa obvious and, thus, invalid, it...
After remaining steady in the first three sessions of the week ended Sept. 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off. Barring anything COVID-19-related , the news flow was fairly light ahead of the Labor Day holiday. Amarin Corporation plc (NASDAQ: AMRN ) took a severe beating after losing a patent appeal related to its synthetic fish oil pill Vascepa. The stock lost over 40% during the week, attributable primarily to the adverse ruling and to a smaller extent to the market sell-off. Here are the key catalysts for the unfolding week. Conferences Citi's 15th Annual BioPharma Conference: Sept. 8-11 Wells Fargo 2020 Virtual Healthcare Conference: Sept. 9-10 Baird 2020 Global Healthcare Conference: Sept. 9-10 BTIG Virtual Biotechnology Conference...